{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:03:42Z","timestamp":1790373822677,"version":"4.1.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal.chestnet.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chest"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.chest.2021.06.017","type":"journal-article","created":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T17:28:05Z","timestamp":1623950885000},"page":"1232-1240","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Pulmonary Complications in Cystic Fibrosis: Past, Present, and Future"],"prefix":"10.1016","volume":"160","author":[{"given":"Christina M.","family":"Mingora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick A.","family":"Flume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.chest.2021.06.017_bib1","series-title":"Patient Registry 2019 Annual Data Report","year":"2020"},{"issue":"19","key":"10.1016\/j.chest.2021.06.017_bib2","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1056\/NEJMra043184","article-title":"Cystic fibrosis","volume":"352","author":"Rowe","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.chest.2021.06.017_bib3","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1378\/chest.128.2.720","article-title":"Pneumothorax in cystic fibrosis","volume":"128","author":"Flume","year":"2005","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.chest.2021.06.017_bib4","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1378\/chest.128.2.729","article-title":"Massive hemoptysis in cystic fibrosis","volume":"128","author":"Flume","year":"2005","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.chest.2021.06.017_bib5","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.chest.2020.09.084","article-title":"Pulmonary exacerbations in adults with cystic fibrosis: a grown-up issue in a changing cystic fibrosis landscape","volume":"159","author":"Stanford","year":"2021","journal-title":"Chest"},{"issue":"19","key":"10.1016\/j.chest.2021.06.017_bib6","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"10.1016\/j.chest.2021.06.017_bib7","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A\u00a0CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.chest.2021.06.017_bib8","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1056\/NEJMoa1709846","article-title":"Tezacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del","volume":"377","author":"Taylor-Cousar","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.chest.2021.06.017_bib9","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1056\/NEJMoa1409547","article-title":"Lumacaftor-ivacaftor in patients with cystic fibrosis homozygous for Phe508del CFTR","volume":"373","author":"Wainwright","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.chest.2021.06.017_bib10","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1164\/rccm.201002-0157OC","article-title":"Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax","volume":"182","author":"Flume","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.chest.2021.06.017_bib11","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1378\/chest.119.2.590","article-title":"Management of spontaneous pneumothorax: an American College of Chest Physicians Delphi consensus statement","volume":"119","author":"Baumann","year":"2001","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.chest.2021.06.017_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.healun.2014.06.014","article-title":"A\u00a0consensus document for the selection of lung transplant candidates: 2014\u2014an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation","volume":"34","author":"Weill","year":"2015","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"10","key":"10.1016\/j.chest.2021.06.017_bib13","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1164\/rccm.201904-0761LE","article-title":"One-way endobronchial valves as management for persistent air leaks: a preview of what\u2019s to come?","volume":"200","author":"Bermea","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.chest.2021.06.017_bib14","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.1016\/j.jcf.2020.03.014","article-title":"Endobronchial valve treatment of persistent alveolopleural fistulae in a patient with cystic fibrosis and empyema","volume":"19","author":"Bongers","year":"2020","journal-title":"J\u00a0Cyst Fibros"},{"issue":"3","key":"10.1016\/j.chest.2021.06.017_bib15","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.healun.2011.09.007","article-title":"Endobronchial valve therapy for pneumothorax as a bridge to lung transplantation","volume":"31","author":"Fischer","year":"2012","journal-title":"J\u00a0Heart Lung Transplant"},{"issue":"5","key":"10.1016\/j.chest.2021.06.017_bib16","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/j.athoracsur.2015.05.073","article-title":"Endobronchial valves in the treatment of persistent air leaks","volume":"100","author":"Hance","year":"2015","journal-title":"Ann Thorac Surg"},{"issue":"3","key":"10.1016\/j.chest.2021.06.017_bib17","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/ppul.1950150311","article-title":"Cystic Fibrosis Foundation consensus conference report on pulmonary complications of cystic fibrosis","volume":"15","author":"Schidlow","year":"1993","journal-title":"Pediatr Pulmonol"},{"issue":"5","key":"10.1016\/j.chest.2021.06.017_bib18","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jcf.2015.02.003","article-title":"Risk of hemoptysis in cystic fibrosis clinical trials: a retrospective cohort study","volume":"14","author":"Thompson","year":"2015","journal-title":"J\u00a0Cyst Fibros"},{"issue":"3","key":"10.1016\/j.chest.2021.06.017_bib19","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1111\/crj.13132","article-title":"Hemoptysis from the perspective of people with cystic fibrosis","volume":"14","author":"Rom\u00e0n","year":"2020","journal-title":"Clin Respir J"},{"issue":"6","key":"10.1016\/j.chest.2021.06.017_bib20","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.chest.2019.02.010","article-title":"Antifibrinolytic agents for hemoptysis management in adults with cystic fibrosis","volume":"155","author":"Al-Samkari","year":"2019","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.chest.2021.06.017_bib21","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.chest.2015.10.016","article-title":"Inhaled tranexamic acid as an alternative for hemoptysis treatment","volume":"149","author":"Segrelles Calvo","year":"2016","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.chest.2021.06.017_bib22","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.chest.2018.09.026","article-title":"Inhaled tranexamic acid for hemoptysis treatment: a randomized controlled trial","volume":"154","author":"Wand","year":"2018","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.chest.2021.06.017_bib23","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jvir.2019.08.028","article-title":"Bronchial artery embolization for hemoptysis in cystic fibrosis patients: a 17-year review","volume":"31","author":"Martin","year":"2020","journal-title":"J\u00a0Vasc Interv Radiol"},{"issue":"6","key":"10.1016\/j.chest.2021.06.017_bib24","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1097\/01.RVI.0000222822.82659.50","article-title":"Bronchial artery embolization in adults with cystic fibrosis: impact on the clinical course and survival","volume":"17","author":"Vidal","year":"2006","journal-title":"J\u00a0Vasc Interv Radiol"},{"issue":"8","key":"10.1016\/j.chest.2021.06.017_bib25","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1007\/s00270-017-1626-0","article-title":"Outcomes following bronchial artery embolisation for haemoptysis in cystic fibrosis","volume":"40","author":"Flight","year":"2017","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"3","key":"10.1016\/j.chest.2021.06.017_bib26","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1055\/s-0032-1326923","article-title":"Bronchial artery embolization","volume":"29","author":"Lorenz","year":"2012","journal-title":"Semin Intervent Radiol"},{"issue":"1","key":"10.1016\/j.chest.2021.06.017_bib27","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1055\/s-0031-1273940","article-title":"Bronchial artery embolization for hemoptysis","volume":"28","author":"Sopko","year":"2011","journal-title":"Semin Intervent Radiol"},{"issue":"4","key":"10.1016\/j.chest.2021.06.017_bib28","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1016\/j.chest.2016.03.009","article-title":"Deaths related to bronchial arterial embolization in patients with cystic fibrosis: three cases and an institutional review","volume":"150","author":"Town","year":"2016","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.chest.2021.06.017_bib29","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.chest.2017.01.019","article-title":"Heterogeneity in survival in adult patients with cystic fibrosis with FEV1\u00a0< 30%\u00a0of predicted in the United States","volume":"151","author":"Ramos","year":"2017","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.chest.2021.06.017_bib30","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jcf.2020.02.015","article-title":"Cystic Fibrosis Foundation consensus guidelines for the care of individuals with advanced cystic fibrosis lung disease","volume":"19","author":"Kapnadak","year":"2020","journal-title":"J\u00a0Cyst Fibros"},{"issue":"2","key":"10.1016\/j.chest.2021.06.017_bib31","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jcf.2018.02.006","article-title":"ECFS best practice guidelines: the 2018 revision","volume":"17","author":"Castellani","year":"2018","journal-title":"J\u00a0Cyst Fibros"},{"issue":"7","key":"10.1016\/j.chest.2021.06.017_bib32","article-title":"Oxygen therapy for cystic fibrosis","volume":"2013","author":"Elphick","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.chest.2021.06.017_bib33","article-title":"Non-invasive ventilation for cystic fibrosis","volume":"2","author":"Moran","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"10.1016\/j.chest.2021.06.017_bib34","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1111\/resp.13604","article-title":"Non-invasive ventilation versus oxygen therapy in cystic fibrosis: a 12-month randomized trial","volume":"24","author":"Milross","year":"2019","journal-title":"Respirology"},{"issue":"3","key":"10.1016\/j.chest.2021.06.017_bib35","doi-asserted-by":"crossref","first-page":"466","DOI":"10.4187\/respcare.07862","article-title":"Noninvasive ventilation in cystic fibrosis: clinical indications and outcomes in a large UK adult cystic fibrosis center","volume":"66","author":"Spoletini","year":"2020","journal-title":"Respir Care"},{"issue":"1","key":"10.1016\/j.chest.2021.06.017_bib36","doi-asserted-by":"crossref","first-page":"1801913","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.chest.2021.06.017_bib37","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.recesp.2016.01.002","article-title":"2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"69","author":"Gali\u00e8","year":"2016","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"issue":"8","key":"10.1016\/j.chest.2021.06.017_bib38","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1164\/rccm.201407-1382OC","article-title":"Pulmonary hypertension in cystic fibrosis with advanced lung disease","volume":"190","author":"Hayes","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"3 Pt 1","key":"10.1016\/j.chest.2021.06.017_bib39","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1164\/ajrccm.162.3.9910102","article-title":"Outcome of patients with cystic fibrosis awaiting lung transplantation","volume":"162","author":"Vizza","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.chest.2021.06.017_bib40","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1378\/chest.115.5.1321","article-title":"Pulmonary hypertension and cardiac function in adult cystic fibrosis: role of hypoxemia","volume":"115","author":"Fraser","year":"1999","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.chest.2021.06.017_bib41","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1097\/MCP.0b013e3283659e9f","article-title":"Pulmonary hypertension survival effects and treatment options in cystic fibrosis","volume":"19","author":"Tonelli","year":"2013","journal-title":"Curr Opin Pulm Med"},{"issue":"1","key":"10.1016\/j.chest.2021.06.017_bib42","doi-asserted-by":"crossref","first-page":"1801914","DOI":"10.1183\/13993003.01914-2018","article-title":"Pulmonary hypertension in chronic lung disease and hypoxia","volume":"53","author":"Nathan","year":"2019","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.chest.2021.06.017_bib43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0186770","article-title":"Critical illness among adults with cystic fibrosis in Texas, 2004-2013: patterns of ICU utilization, characteristics, and outcomes","volume":"12","author":"Oud","year":"2017","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.chest.2021.06.017_bib44","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1164\/ajrccm.163.2.2003076","article-title":"Outcomes of intensive care unit care in adults with cystic fibrosis","volume":"163","author":"Sood","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.chest.2021.06.017_bib45","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jcf.2019.03.002","article-title":"Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines","volume":"18","author":"Ramos","year":"2019","journal-title":"J\u00a0Cyst Fibros"},{"issue":"1","key":"10.1016\/j.chest.2021.06.017_bib46","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12890-017-0367-9","article-title":"Cystic fibrosis physicians\u2019 perspectives on the timing of referral for lung transplant evaluation: a survey of physicians in the United States","volume":"17","author":"Ramos","year":"2017","journal-title":"BMC Pulm Med"},{"issue":"1","key":"10.1016\/j.chest.2021.06.017_bib47","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jcf.2015.08.004","article-title":"Advance care planning in cystic fibrosis: current practices, challenges, and opportunities","volume":"15","author":"Dellon","year":"2016","journal-title":"J\u00a0Cyst Fibros"},{"issue":"2","key":"10.1016\/j.chest.2021.06.017_bib48","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1183\/13993003.00592-2015","article-title":"Report of the European Respiratory Society\/European Cystic Fibrosis Society task force on the care of adults with cystic fibrosis","volume":"47","author":"Elborn","year":"2016","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.chest.2021.06.017_bib49","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.jpainsymman.2019.08.017","article-title":"Opportunities to improve utilization of palliative care among adults with cystic fibrosis: a systematic review","volume":"58","author":"Marmor","year":"2019","journal-title":"J\u00a0Pain Symptom Manage"},{"issue":"3","key":"10.1016\/j.chest.2021.06.017_bib50","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jcf.2019.11.010","article-title":"Prevalence of unmet palliative care needs in adults with cystic fibrosis","volume":"19","author":"Trandel","year":"2020","journal-title":"J\u00a0Cyst Fibros"},{"issue":"1","key":"10.1016\/j.chest.2021.06.017_bib51","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1089\/jpm.2020.0311","article-title":"Models of palliative care delivery for individuals with cystic fibrosis: Cystic Fibrosis Foundation evidence-informed consensus guidelines","volume":"24","author":"Kavalieratos","year":"2021","journal-title":"J\u00a0Palliat Med"},{"issue":"1","key":"10.1016\/j.chest.2021.06.017_bib52","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1378\/chest.13-2397","article-title":"Effects of ivacaftor in patients with cystic fibrosis who carry the G551D mutation and have severe lung disease","volume":"146","author":"Barry","year":"2014","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.chest.2021.06.017_bib53","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jcf.2013.05.006","article-title":"Effects of ivacaftor on severely ill patients with cystic fibrosis carrying a G551D mutation","volume":"12","author":"Hebestreit","year":"2013","journal-title":"J\u00a0Cyst Fibros"},{"issue":"1","key":"10.1016\/j.chest.2021.06.017_bib54","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jcf.2015.01.008","article-title":"Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: safety and efficacy in an expanded access program in the United States","volume":"15","author":"Taylor-Cousar","year":"2016","journal-title":"J\u00a0Cyst Fibros"},{"issue":"155","key":"10.1016\/j.chest.2021.06.017_bib55","doi-asserted-by":"crossref","first-page":"190112","DOI":"10.1183\/16000617.0112-2019","article-title":"Impact of CFTR modulator use on outcomes in people with severe cystic fibrosis lung disease","volume":"29","author":"Shteinberg","year":"2020","journal-title":"Eur Respir Rev"},{"issue":"2","key":"10.1016\/j.chest.2021.06.017_bib56","doi-asserted-by":"crossref","first-page":"2003079","DOI":"10.1183\/13993003.03079-2020","article-title":"The efficacy of elexacaftor\/tezacaftor\/ivacaftor in patients with cystic fibrosis and advanced lung disease","volume":"57","author":"O\u2019Shea","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.chest.2021.06.017_bib57","first-page":"A6203","article-title":"Promising results with elexacaftor\/tezacaftor\/ivacaftor use in cystic fibrosis patients with advanced lung disease: beyond the clinical trial inclusion criteria","volume":"201","author":"Bowen","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.chest.2021.06.017_bib58","series-title":"A\u00a0multi-center retrospective analysis of the clinical efficacy of elexacaftor-tezacaftor-ivacaftor in patients with advanced lung disease","author":"Bermingham","year":"2020"},{"key":"10.1016\/j.chest.2021.06.017_bib59","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1164\/rccm.202011-4153OC","article-title":"Rapid improvement after starting elexacaftor-tezacaftor-ivacaftor in patients with cystic fibrosis and advanced pulmonary disease","volume":"240","author":"Burgel","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.chest.2021.06.017_bib60","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/thoraxjnl-2017-210394","article-title":"Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor","volume":"73","author":"Bessonova","year":"2018","journal-title":"Thorax"},{"issue":"7","key":"10.1016\/j.chest.2021.06.017_bib61","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1164\/rccm.201503-0578OC","article-title":"Sustained benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data","volume":"192","author":"Sawicki","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.chest.2021.06.017_bib62","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S2213-2600(16)30427-1","article-title":"Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study","volume":"5","author":"Konstan","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.chest.2021.06.017_bib63","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S2213-2600(20)30510-5","article-title":"Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study","volume":"9","author":"Flume","year":"2021","journal-title":"Lancet Respir Med"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369221011272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369221011272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T08:36:32Z","timestamp":1757925392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369221011272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0012369221011272"],"URL":"https:\/\/doi.org\/10.1016\/j.chest.2021.06.017","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pulmonary Complications in Cystic Fibrosis: Past, Present, and Future","name":"articletitle","label":"Article Title"},{"value":"Chest","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chest.2021.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}